Genitourinary Cancers

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy combination studies for the treatment of patients with urothelial carcinoma.

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma.

Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.

Kerstin Junker, MD, PhD, discusses the need to identify prognostic biomarkers for patients with RCC.

Thomas Powles MBBS, MRCP, MD, discusses the findings from the CheckMate-214 trial, as well as continuing studies in immunotherapy and targeted therapy in kidney cancer.

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses recent trials in kidney cancer.

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses the combination of immunotherapy with IDO inhibitors for patients with urothelial carcinoma.

Antitumor activity of the combination of axitinib (Inlyta) and pembrolizumab (Keytruda) is superior to that expected from axitinib or PD-1/PD-L1 pathway inhibitor monotherapy in treatment-naïve patients with advanced renal cell carcinoma.

Cabozantinib (Cabometyx) improved progression-free survival as initial systemic therapy across subgroups of patients with intermediate- and poor-risk advanced RCC enrolled in the randomized phase II CABOSUN trial.

Erdafitinib showed responses in more than one-third of patients with pretreated metastatic or unresectable FGFR alteration-positive urothelial carcinoma.

Two-year follow-up data showed sustained improvements in overall survival with pembrolizumab over chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer.

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses 2-year follow-up results from the phase III KEYNOTE-045 trial of pembrolizumab (Keytruda) versus chemotherapy in recurrent, advanced urothelial carcinoma during the 2018 Genitourinary Cancers Symposium.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a phase IIIb safety study of fixed-dose durvalumab (Imfinzi) and tremelimumab in patients with advanced urothelial carcinoma.

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, discusses a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial carcinoma.

William C. Huang, MD, discusses the transition from open cystectomy to minimally invasive robotic-assisted surgery in the management of muscle-invasive bladder cancer.

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC).

Selective bladder preservation has been suggested as a potential alternative to cystectomy in patients with bladder cancer who have a transitional cell carcinoma pathology.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

Arjun V. Balar, MD, discusses the landscape of current and future standards of care for immunotherapy in bladder and kidney cancer.